Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
Date:6/17/2011

f 60 Tablets

50458-593-60

OlG175

August 2012RISPERDAL® (risperidone) is used for the treatment of schizophrenia in adults and adolescents ages 13-17 years.

RISPERDAL® (risperidone) is used alone or in combination with other medicines (valproate or lithium) in adults for the short-term treatment of bipolar mania; or alone in adults, children and adolescents ages 10-17 years for the short-term treatment of bipolar mania.

RISPERDAL® (risperidone) is used for the treatment of irritability associated with autistic disorder in children and adolescents ages 5-16 years.

Ortho-McNeil-Janssen Pharmaceuticals, Inc. has initiated these recalls in the U.S. and Puerto Rico at the wholesale and retail (pharmacy) level and is communicating this information to these customers.  The company does not anticipate a product shortage resulting from this action.

Patients should not stop taking their medication.  Anyone experiencing an uncharacteristic odor associated with RISPERDAL® 3mg Tablets or risperidone 2mg Tablets should return the tablets to their pharmacist, and contact their healthcare professional if they have questions.  Patients or healthcare professionals can contact the Medical Information Recall Line at 1-800-634-8977 (Monday – Friday, 9 am – 5 pm ET).  Information can also be found on www.risperdal.com and www.patriotpharmaceuticals.com

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or through regular mail or by fax.

  • Online:  www.fda.gov/medwatch/report.htm
  • Regular Mail:  Use postage-paid, pre-addressed Form FDA 3500 available at:  w
    '/>"/>

  • SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
    2. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
    3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
    4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
    5. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
    6. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
    7. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
    8. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
    9. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
    10. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    11. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... , Oct. 30, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release third quarter 2014 financial results on Wednesday, ... The Company,s management will hold a conference call ... 2014, which is 8:30 p.m., Beijing Time on November ...
    (Date:10/30/2014)... , La fórmula de ... adquirir tolerancia a la proteína de leche de ... la leche de la vaca (APLV) es la principal alergia ... la APLV se trataba eliminando las proteínas lácteas ... es posible adquirir tolerancia oral en un número ...
    (Date:10/30/2014)... 2014 The global newborn screening market ... technology, product, and geography. The mass spectrometry market ... in the newborn screening market by technology, during ... to various nations opting for expanded newborn screening. ... for expanded newborn screening. Furthermore, various conferences and ...
    Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
    ... 11 El Camino Hospital, the hospital of Silicon ... da Vinci® Si HD Surgical Systems. Physicians performed more ... expect the number to increase in 2010 as more ... for more minimally invasive procedures. The new systems feature ...
    ... BROOMFIELD, Colo., Nov. 11 Accera, Inc., a biotechnology company ... that it will present at Lazard Capital Markets 6th Annual ... in New York. , Steve Orndorff, Ph.D., founder, president ... an update on Axona (TM) on Tuesday, November 17 ...
    Cached Medicine Technology:El Camino Hospital Expands Robotic Surgery Program 2El Camino Hospital Expands Robotic Surgery Program 3El Camino Hospital Expands Robotic Surgery Program 4Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference 2
    (Date:10/30/2014)... 2014 USARAD Holdings Inc ... and specialty telemedicine solutions provider, including SecondOpinions.com ... existing teleradiology services at Mission Bend ER, it ... telemedicine services, to the state-of-the-art, 24/7, freestanding ER ... of this innovative partnership, there will be many ...
    (Date:10/30/2014)... WA (PRWEB) October 30, 2014 Sound Telecom, ... decision infographic that will assist people any time they wonder, ... discover the right answer by leading them through a series ... resolution to their initial query. , There are many considerations ... not to use an answering service . This decision ...
    (Date:10/30/2014)... News) -- Many U.S. colleges have indoor tanning ... increases the risk for skin cancer, researchers report. ... white women, so colleges should adopt tanning-free policies, ... "Public health efforts are needed to raise ... harms that indoor tanning poses to young adults ...
    (Date:10/30/2014)... 29, 2014) – A new standard of care for ... following a multi-year study published in the latest edition ... , The research, led by John Wagner, Jr., M.D., ... at the University of Minnesota and a researcher in ... in children with acute leukemia and myelodysplastic syndrome who ...
    (Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
    Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:New insights into the development of ciliopathies 2
    ... the seventh leading cause of cancer death worldwide, the ... group and gender. Esophageal cancer is thought to be ... with the host genome. Researchers have long been seeking ... conducted on gene-environment interaction and gene polymorphisms for esophageal ...
    ... intellectual property laws devalue the "repurposing" of existing ... life-saving treatments, a Portland researcher contends. , S. ... behavioral neuroscience in the Oregon Health & Science ... Affairs Medical Center, writes in a letter appearing ...
    ... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today ... Pharmaceuticals GmbH (Merz) for sales,by Merz and its ... severe Alzheimer,s disease for the quarter ended June ... royalty payments compared to,the same quarter last year, ...
    ... Oct. 31 MAP,Pharmaceuticals, Inc. (Nasdaq: ... the initiation of a Phase 2a clinical ... asthma and chronic obstructive,pulmonary disease (COPD). ... and a long-acting,beta2-agonist delivered to the respiratory ...
    ... and Offshore Healthcare Expertise and ... Service Delivery Capabilities EL SEGUNDO, Calif. ... CSC ) and,First Consulting Group, Inc. (Nasdaq: FCGI ) today ... through which CSC will acquire,First Consulting Group (FCG) in an all-cash ...
    ... EDMONTON, Oct. 31 /PRNewswire-FirstCall/ - BioMS Medical Corp ... multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... Rodman and Renshaw 9th Annual Healthcare Conference in ... 3:20 pm (Local Time), WHERE: New York ...
    Cached Medicine News:Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Old drugs need 'repurposing' for new uses, physician says 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:CSC Agrees to Acquire First Consulting Group 2Health News:CSC Agrees to Acquire First Consulting Group 3Health News:CSC Agrees to Acquire First Consulting Group 4Health News:CSC Agrees to Acquire First Consulting Group 5Health News:BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
    ... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
    Inquire...
    ... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
    ... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
    Medicine Products: